Literature DB >> 29804142

Tight correlation between FoxM1 and FoxP3+ Tregs in gastric cancer and their clinical significance.

Xiaoxiao Li1, Kai Ma2, Shanai Song1, Fangzhen Shen1, Tao Kuang1, Yingqian Zhu1, Zimin Liu3.   

Abstract

The aim of the present study was to investigate the expression of Forkhead box transcription M1 (FoxM1) and Forkhead box transcription P3 (FoxP3) in gastric cancer tissues in order to reveal any correlation between FoxM1, FoxP3 and clinicopathological parameters. Their clinical significance in gastric cancer was also investigated. Immunohistochemistry was used to detect the expression of FoxM1 and FoxP3 in gastric cancer and para-cancer tissues. The clinical significance of FoxM1 and FoxP3 in gastric cancer was explored, and the association between FoxM1 and FoxP3 was further analyzed. As a result, the overexpression of FoxM1 and FoxP3 was evident in gastric cancer (P < 0.001). FoxM1 overexpression was showed to be correlated with late AJCC stage (P = 0.025), while positive tumoral FoxP3 expression was associated with deeper invasion (P = 0.020), lymph node metastasis (P = 0.019) and later AJCC stage (P = 0.024). Overexpression of FoxM1 or FoxP3 was revealed to be negative prognostic factors for survival duration (P < 0.05), whereas only FoxM1 was shown to be independently associated with prognosisin gastric cancer after multivariate analysis (P = 0.020). A significant and positive correlation between FoxM1 and FoxP3 expressions was finally confirmed (P = 0.001). This significantly positive correlation between FoxM1 and FoxP3 prompts that FoxM1 may induce immune inhibition by recruiting FoxP3+ Tregs, leading to the progression of carcinogenesis, invasion and metastasis.

Entities:  

Keywords:  FoxM1; FoxP3; Gastric cancer; Tregs

Mesh:

Substances:

Year:  2018        PMID: 29804142     DOI: 10.1007/s10238-018-0505-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  36 in total

Review 1.  Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.

Authors:  Fung Zhao; Eric W-F Lam
Journal:  Front Med       Date:  2012-11-03       Impact factor: 4.592

2.  Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Limin Xia; Wenjie Huang; Dean Tian; Hongwu Zhu; Yongguo Zhang; Hao Hu; Daiming Fan; Yongzhan Nie; Kaichun Wu
Journal:  J Hepatol       Date:  2012-05-18       Impact factor: 25.083

Review 3.  Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression.

Authors:  Adam W Mailloux; M Rita I Young
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

4.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention.

Authors:  Siddavaram Nagini
Journal:  World J Gastrointest Oncol       Date:  2012-07-15

7.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

Authors:  Fumiko Ichihara; Koji Kono; Akihiro Takahashi; Hiromichi Kawaida; Hidemitsu Sugai; Hideki Fujii
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

8.  PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors.

Authors:  Matthias Merkenschlager; Harald von Boehmer
Journal:  J Exp Med       Date:  2010-07-05       Impact factor: 14.307

9.  Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients.

Authors:  X Li; W Qi; R Yao; D Tang; J Liang
Journal:  Clin Transl Oncol       Date:  2013-07-20       Impact factor: 3.405

10.  FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis.

Authors:  Nuo Xu; Deshui Jia; Wenfeng Chen; Hao Wang; Fanglei Liu; Haiyan Ge; Xiaodan Zhu; Yuanlin Song; Xin Zhang; David Zhang; Di Ge; Chunxue Bai
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

View more
  4 in total

Review 1.  Dietary phytochemicals as the potential protectors against carcinogenesis and their role in cancer chemoprevention.

Authors:  Alena Liskova; Patrik Stefanicka; Marek Samec; Karel Smejkal; Pavol Zubor; Tibor Bielik; Kristina Biskupska-Bodova; Taeg Kyu Kwon; Jan Danko; Dietrich Büsselberg; Mariusz Adamek; Luis Rodrigo; Peter Kruzliak; Aleksandr Shleikin; Peter Kubatka
Journal:  Clin Exp Med       Date:  2020-02-03       Impact factor: 3.984

2.  A CT-based radiomics signature for evaluating tumor infiltrating Treg cells and outcome prediction of gastric cancer.

Authors:  Xujie Gao; Tingting Ma; Shuai Bai; Ying Liu; Yuwei Zhang; Yupeng Wu; Hui Li; Zhaoxiang Ye
Journal:  Ann Transl Med       Date:  2020-04

3.  Immune Cell Landscape in Gastric Cancer.

Authors:  Yang Yang; Wei He; Zi-Rui Wang; Yu-Jiao Wang; Lan-Lan Li; Jian-Zhong Lu; Yan Tao; Jing Zhang; Sheng-Jun Fu; Zhi-Ping Wang; Shan-Hui Liu
Journal:  Biomed Res Int       Date:  2021-01-09       Impact factor: 3.411

4.  Transcriptional activation of Proteasome 26S non-ATPase subunit 7 by forkhead box P3 participates in gastric cancer cell proliferation and apoptosis.

Authors:  Yujie Xu; Dingmao Wang; Guodong Zhao
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.